Navigation Links
Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
Date:2/20/2008

PHILADELPHIA, Feb. 20 /PRNewswire/ -- According to Anapol Schwartz (http://www.anapolschwartz.com/) attorney James Ronca (http://www.anapolschwartz.com/attorneys/jim_ronca.shtml), a New England Journal of Medicine study (http://content.nejm.org/cgi/content/short/358/8/771?query=TOC) (to be released in the February 21, 2008, print edition) confirms that Bayer AG's blood-clotting drug Trasylol(R), used in coronary artery bypass graft (CABG) procedures, causes kidney/renal failure and increases mortality risk. While initial findings of the study, commissioned by Bayer, were sent to the drug company and the FDA in 2006, this is the first time the final results have been published in full.

Ronca, who is one of the chairs of the national Trasylol(R) litigation, and represents a dozen families and victims (see Trasylol(R) lawsuit (http://www.anapolschwartz.com/practices/trasylol/) and a recent wrongful death complaint (http://www.anapolschwartz.com/practices/trasylol/thompson-complaint.pdf) filed in Philadelphia), argues this study reinforces inherent problems in the FDA's screening process and opens the floodgates for additional litigation.

"According to published sources, thousands may have died from Trasylol(R), when this could have been prevented. Again, we have another example of the FDA not protecting the public -- and the safety of individuals taking a back seat to company profits," says Ronca, who leads advocacy initiatives to raise awareness about Trasylol's(R) side effects.

Pulled by Bayer from the market in November 2007 in response to FDA concerns, Trasylol(R) is administered by an anesthesiologist during CABG surgery (http://www.anapolschwartz.com/practices/trasylol/thompson-complaint.pdf) to limit bleeding. Affected patients typically experience kidney/renal failure symptoms within 48 hours. Many, however, are unaware they have received the drug, complicating diagnosis.

"These findings should further educate the public about Trasylol's(R) dangers, and open the door for victims, and those who don't realize they are victims, to receive remuneration for their injuries," stresses Ronca, who has served as counsel to victims in product liability cases involving Baycol, LOTRONEX, hormone replacement therapy and breast implants.

Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley is a personal injury firm with law offices in Philadelphia, Reading, Media, and Harrisburg, Pa., as well as Cherry Hill, N.J. (http://www.anapolschwartz.com/contactus.shtml) The firm is a multi-faceted practice with a tradition of excellence in medical malpractice law, pharmaceutical mass tort, toxic tort, class actions, products liability, automobile, securities and wrongful termination litigation. Since its founding in 1977, the firm has grown to over 30 attorneys, and compiled a record of success exceptional among its peers.

Contact: Alexandra Kane-Weiss/Jennifer Wasilisin

215-793-4666

akaneweiss@startoplin.com

jwasilisin@startoplin.com


'/>"/>
SOURCE Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Driven Healthcare Continues To Make Its Mark on Indianapolis Market
2. St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards
3. Brown Mackie College - Indianapolis Announces New Degree Program in Occupational Therapy
4. Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council
6. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark
7. AHIP Statement on New York Attorney Generals Announcement
8. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
9. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
10. Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit
11. Statement from AAJ President Kathleen Flynn Peterson on ATRAs Latest Attack on Civil Justice Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... The medical profession is well aware that heart attacks do indeed increase ... attacks among 138,602 people recorded a 35% higher number of heart attacks in December ... course–no time of year is a good time for a heart attack! In the ...
(Date:12/7/2016)... AZ (PRWEB) , ... December ... ... ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus for ... WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment modalities ...
(Date:12/7/2016)... ... 2016 , ... “Tomorrow Trump Goes To Washington”: a brief but engaging ... and to America. “Tomorrow Trump Goes To Washington” is the creation of published author, ... this country. , Nancy attributes her patriotic nature to her WWII veteran father. ...
(Date:12/7/2016)... , ... (PRWEB) December 07, 2016 , ... ... nonprofit for individuals impacted by cerebral cavernous angiomas, was awarded a grant from ... a patient engagement program. New Mexico has more people with cavernous angioma than ...
(Date:12/7/2016)... ... ... NuevaCare, a leading home care agency based in San Mateo but serving ... part of its ambitious website relaunch. As Bay Area clients scramble to find quality ... their city. The new site has several key city-specific pages to address this need. ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 Anaplastic Oligoastrocytoma - ... Markets Direct,s latest Pharmaceutical and Healthcare disease pipeline ... provides an overview of the Anaplastic Oligoastrocytoma (Oncology) ... tumor that forms when two types of cells ... increase in number to form a mass. These ...
(Date:12/6/2016)... Eurofins Genomics today announced it has ... American Pathologists (CAP) and certification under the Clinical ... in Louisville, KY , where ... "Our new CLIA-licensed and CAP-accredited clinical ... considered the ,Gold Standard, method for validation of ...
(Date:12/6/2016)... , Dec. 6, 2016   ... clinical-stage medical dermatology and aesthetics company, today ... privately held specialty pharmaceutical company focused on ... skin conditions, including psoriasis, atopic dermatitis and ... agreement, Sienna will make an undisclosed upfront ...
Breaking Medicine Technology: